Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.Helena A. Yu, Melissa L. Johnson, Julia K. Rotow et al.|Journal of Clinical Oncology|2026Cited by 1
Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.Julia K. Rotow, Xiuning Le, Christina S. Baik et al.|Journal of Clinical Oncology|2026Cited by 0